NCT04961437

Brief Summary

Modern management of acute respiratory failure aims to relieve dyspnea and anxiety by providing a non-invasive respiratory support. This approach tries to avoid endotracheal intubation, patient self inflicted lung injuries (PSILI) and diaphragmatic dysfunction. The present study aims to evaluate dyspnea, pulmonary regional ventilation and diaphragmatic function in patients with hypoxemic acute respiratory failure by different observations, and to bring risk factor for intubation out.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
55

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 18, 2021

Completed
26 days until next milestone

First Posted

Study publicly available on registry

July 14, 2021

Completed
28 days until next milestone

Study Start

First participant enrolled

August 11, 2021

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 22, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 22, 2025

Completed
Last Updated

March 6, 2026

Status Verified

March 1, 2026

Enrollment Period

3.9 years

First QC Date

June 18, 2021

Last Update Submit

March 5, 2026

Conditions

Keywords

Acute respiratory failurediaphragmdyspneaEIT

Outcome Measures

Primary Outcomes (1)

  • Oro-tracheal intubation

    Patients who will be intubated within the 7 days after admission in the ICU

    7 days after admission in the ICU

Secondary Outcomes (8)

  • Diaphragmatic function

    2 days after inclusion

  • Diaphragmatic function

    2 days after inclusion

  • lung regional ventilation

    2 days after inclusion

  • Dyspnea evaluation

    28 days after inclusion

  • Dyspnea evaluation

    28 days after inclusion

  • +3 more secondary outcomes

Study Arms (1)

Patients with de novo acute respiratory failure

The following tests will be performed as part of the research (these tests are usually performed as part of routine care but not routinely and comprehensively): * A diaphragmatic ultrasound in the half-seated position. Diaphragmatic excursion and thickening fraction will be measured in the right hemi-diaphragm. * A 10-minute reference acquisition. They will be performed at inclusion, H2, H4 and H48.

Other: Diaphragmatic ultrasound and electrical impedance tomography

Interventions

A diaphragmatic ultrasound in a half sitting position. The diaphragmatic excursion and the thickening fraction of the right hemi-diaphragm will be measured. \- Acquisition of 10 minutes of regional pulmonary ventilation by electrical impedance tomography.

Patients with de novo acute respiratory failure

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with de novo acute respiratory failure

You may qualify if:

  • Age \> 18
  • Acute respiratory insufficiency defined by the three following items :
  • PaO2/ FiO2 \<300
  • Respiratory rate \> 25/min
  • Oxygen support \> 10L/min or High Flow nasal oxygen (HFNO)
  • Non opposition by the patient to be included
  • Social insurance

You may not qualify if:

  • Respiratory acidosis (pH \< 7,35 PaCO2 \> 45mmHg or 6kPa)
  • Chronic respiratory disease ( COPD, bronchiectasis…)
  • Cardiogenic Acute lung oedema
  • Non intubation decision at randomisation
  • Contraindication for Electro-impedance tomography-belt placement (chest trauma with rib fractures, thoracic wound, chest tube).
  • Uncommunicative patient (Glasgow coma scale \<12)
  • Guardianship or curators for vulnerable patients.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Groupe Hospitalier Pitié-Salpêtrière", Intensive care unit

Paris, 75013, France

Location

MeSH Terms

Conditions

Dyspnea

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Martin DRES, MD PhD

    Assistance Publique - Hôpitaux de Paris

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 18, 2021

First Posted

July 14, 2021

Study Start

August 11, 2021

Primary Completion

July 22, 2025

Study Completion

July 22, 2025

Last Updated

March 6, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will share

The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor
Access Criteria
Researchers who provide a methodologically sound proposal.

Locations